Currently, 18F-fluorodeoxyglucose (18F-FDG) is the most widely used tumor imaging agent in clinical practice. However, the production of 18F requires accelerators and is associated with relatively high diagnostic costs, which to some extent limits its widespread clinical application. In comparison to Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) devices are more abundant and offer lower diagnostic expenses. With the utilization of Cadmium Zinc Telluride (CZT) crystals in SPECT and advancements in image reconstruction techniques, the resolution and sensitivity of SPECT is continually improving. Therefore, the development of a simplified and cost-effective novel SPECT tumor imaging agent holds significant practical significance. This study involved the design and synthesis of a glucose-derived ligand with a linker containing seven methylene units and an isonitrile group (CN7DG). The CN7DG ligand was labeled with 99mTc to prepare a more lipophilic 99mTc-CN7DG complex, aiming to investigate a novel SPECT imaging agent for tumor imaging.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
100
Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
RECRUITINGUptake value of 99mTc-CNDG in malignant tumors
The uptake value was measured in the malignant lesions on 99mTc-CNDG SPECT/CT.
Time frame: through study completion, an average of 1 year
Lesions detected by 99mTc-CNDG SPECT/CT
The number of target lesions was calculated by 99mTc-CNDG SPECT/CT
Time frame: through study completion, an average of 1 year
Compared with 18F-FDG PET/CT or CECT
The number of lesions detected by 99mTc-CNDG SPECT/CT was compared with 18F-FDG PET/CT or CECT
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.